Monitor the upcoming definitive proxy statement for the nature of the additional proposal—this could signal a governance change, equity issuance, or strategic transaction. The extended timeline gives the board room to negotiate or solicit support, which may be relevant for a micro-cap with potential activist or financing needs.
Price Chart
Executive Summary
Bone Biologics postponed its 2026 annual meeting from August 11 to September 28, 2026, citing the need to add an additional proposal and allow stockholders more time to consider proxy materials. The new record date is August 6, and the deadline for stockholder submissions is July 26, 2026. This is a routine procedural delay with no material financial impact, though the addition of a new proposal warrants monitoring for potential activist or governance developments.
Key Financial Metrics
Key Facts
- Annual meeting postponed from August 11, 2026 to September 28, 2026.
- New record date set for August 6, 2026.
- Board will add an additional proposal to the proxy statement.
- Stockholder submission deadline extended to July 26, 2026.
- Company is a micro-cap ($2M market cap) with no revenue or earnings disclosed in this filing.
Financial Impact
No financial figures disclosed in this filing.
Risk Factors
- The additional proposal could be dilutive (e.g., equity raise) or involve a contested matter.
- Postponement may indicate internal disagreement or a pending activist campaign.
- Micro-cap status amplifies price sensitivity to any governance or capital structure changes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001493152-26-033938 |
| Document: 0001493152-26-033938-index-headers.html | 0001493152-26-033938 |
| Document: 0001493152-26-033938-index.html | 0001493152-26-033938 |
| Document: 0001493152-26-033938.txt | 0001493152-26-033938 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 25-NSE | $0.4300 | awaiting T+60 | — | $0.3770 (−12.33%) |
Jul 27, 2026 13w ago | EFFECT | $1.03 $0.4105 | ▲ +59.95% | ▲ +63.66% | $0.3770 (+63.22%) |
Jul 20, 2026 14w ago | DEFA14A | $1.11 $0.4300 | ▼ −61.26% | ▼ −65.23% | $0.3770 (−66.04%) |
Jul 17, 2026 14w ago | S-3 | $1.12 $0.4300 | ▲ +61.61% | ▲ +66.45% | $0.3770 (+66.34%) |
Jul 8, 2026 16w ago | Press Release | $1.38 $0.4754 | ▲ +65.55% | ▲ +67.94% | $0.3770 (+72.68%) |
Jul 2, 2026 16w ago | DEFA14A | $1.42 $0.4912 | ▼ −65.41% | ▼ −68.42% | $0.3770 (−73.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers